Clinical Trial Update: Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tenofovir alafenamide added to a failing regimen, followed by a regimen including elvitegravir/cobicistat/emtricitabine/tenofovir alafe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• HIV Infection

Drugs mentioned

• Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide plus atazanavir (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide plus atazanavir)
• Tenofovir alafenamide (tenofovir alafenamide)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV, HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2017-06-12